EMERGENT BIOSOLUTIONS INC. COMMON STOCK

NetDania - New 12 months High: EMERGENT BIOSOLUTIONS INC. COMMON STOCK

02 يوليو 2024 12:02:06 بحسب NetDania Notify

Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

02 يوليو 2024 09:43:07 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

02 يوليو 2024 08:13:43 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million

20 يونيو 2024 07:00:57 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day

06 يونيو 2024 09:02:45 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

10 مايو 2024 07:17:11 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports First Quarter 2024 Financial Results

01 مايو 2024 16:57:22 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

01 مايو 2024 16:10:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

01 مايو 2024 11:03:28 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

30 أبريل 2024 17:26:55 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

22 أبريل 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

28 مارس 2024 08:15:03 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

25 مارس 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

06 مارس 2024 16:31:01 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

29 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

21 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

11 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

09 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

28 نوفمبر 2023 06:59:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

24 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire